Effect of Tepotinib on PK of CYP3A Substrate Midazolam

NCT03628339 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Midazolam
DRUG: Tepotinib

Sponsor

Merck KGaA, Darmstadt, Germany